Copy Link Print Information

Capmatinib dihydrochloride

(Synonyms: INC280 dihydrochloride; INCB28060 dihydrochloride)
31 Cited Publications
Revisión del cliente

Based on 31 publication(s) in Google Scholar

Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.82%
  • No. CAS: 1197376-85-4
  • Fòrmula: C23H19Cl2FN6O
  • Peso molecular:485.34
  • Almacenamiento:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Capmatinib dihydrochloride Chemical Structure
    Capmatinib dihydrochloride Chemical Structure
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
  • Experimental Validation Results for Capmatinib dihydrochloride
No. CAS: 1197376-85-4
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Capmatinib dihydrochloride:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Capmatinib dihydrochloride

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayWB
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • WB

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Capmatinib dihydrochloride Chemical Structure
    Capmatinib dihydrochloride Chemical Structure
    1/16
  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Nature. 2026 Oct;658(8134):241-249.

    Customer Validation
     Plot: relative proliferation of NCI-H3122 WT or NCI-H3122MET (MET overexpressing) cells measured by CTG in response to a dose titration TRI-611 in the presence of the indicated concentrations of Capmatinib for 4 d. Western: levels of the indicated proteins following 14 h treatment of NCI-H3122 (WT) or NCI-H3122MET (MET) with 1 µM TRI-611.

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 17:e00806. [Abstract]

    Customer Validation
     A) Orthotopic inoculated KPC tumors from the control, Capmatinib (INC280) monotherapy, DTA-1 monotherapy and combined therapy groups. B) Quantification of tumor weights under different treatment.Male C57BL/6 mice (KPC cells，orthotopic pancreatic tumor model ), 1) vehicle (5% DMSO + 45% PEG300/5% Tween80 + 50% ddH2O) + IgG control, 2) MET inhibitor monotherapy: INC280 (10 mg kg day−1 for 8 days) + IgG, 3) GITR agonist monotherapy: DTA‐1 (100 µg mouse day−1 for 4 days) + vehicle, and 4) combination therapy: INC280+ DTA‐1. INC280 was formulated in a vehicle solution of DMSO/PEG300/Tween80/ddH₂O (5:45:5:50, v/v) and administered by intraperitoneal injection.

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 17:e00806. [Abstract]

    Customer Validation
     Flowcytometry analysis of GzmB , and TNF-α expression in CD8+ T cells under different treatment. Male C57BL/6 mice (KPC cells，orthotopic pancreatic tumor model ), 1) vehicle (5% DMSO + 45% PEG300/5% Tween80 + 50% ddH2O) + IgG control, 2) MET inhibitor monotherapy: INC280 (Capmatinib, 10 mg kg day−1 for 8 days) + IgG, 3) GITR agonist monotherapy: DTA‐1 (100 µg mouse day−1 for 4 days) + vehicle, and 4) combination therapy: INC280+ DTA‐1. INC280 was formulated in a vehicle solution of DMSO/PEG300/Tween80/ddH2O (5:45:5:50, v/v) and administered by intraperitoneal injection.

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Feb 19;26(4):1766. [Abstract]

    Customer Validation
     In the 3D culture system, MPE primary cells formed stable spheroids within 96 h. Drug sensitivity assays using the 3D tumorsphere model showed that Giotrif (afatinib) at 60 nM and Capmatinib (0.8 nM; 96 h) at 6.5 nM achieved IC50.

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Feb;19(2):474-495. [Abstract]

    Customer Validation
     Capmatinib (0.5,1 μM; 24 h) toxicity was also tested through MTT tests at higher concentration.

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Feb;19(2):474-495. [Abstract]

    Customer Validation
     (A)Graphical representation of tumour volume over time after subcutaneous injection of PC3M Ctrl, PC3M ETV1 and PC3M ERG cells. The tumour volume of the mice was monitored by palpation. (B) Graphical representation of the final tumour volume of mice having been treated or not with Capmatinib.8‐week‐old male NSG‐hHGFki mice (PC3M cells), Capmatinib (10 mg/kg; oral gavage 5 days a week, 30 days).

  • 1/16

    Capmatinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Wayne State University. 2014 Jan.

    Customer Validation
     The c-Met Inhibitor INC280 Reveals HGF Activation of c-Met Leads to β4 Activation. (A) Dose-dependent assay to determine the concentration of INC280 required to prevent HGF-induced c-Met phosphorylation. Cells are pre-treated for two hours with INC280 at the indicated concentrations and then stimulated with 50 ng/mL HGF for 30 minutes. Phosphorylated (upper panel) and total c-Met (lower panel) are analyzed by Western blot. Densitometry represents the ratio of phosphorylated to total c-Met as a p

  • Capmatinib dihydrochloride